Nuveen Asset Management LLC Sells 36,392 Shares of Orthofix Medical Inc. (NASDAQ:OFIX)

Nuveen Asset Management LLC decreased its holdings in Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) by 29.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 88,620 shares of the medical device company's stock after selling 36,392 shares during the quarter. Nuveen Asset Management LLC owned about 0.23% of Orthofix Medical worth $1,547,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the company. Renaissance Technologies LLC grew its stake in Orthofix Medical by 166.9% in the 4th quarter. Renaissance Technologies LLC now owns 82,190 shares of the medical device company's stock valued at $1,435,000 after acquiring an additional 51,399 shares during the last quarter. Barclays PLC raised its holdings in Orthofix Medical by 38.8% in the third quarter. Barclays PLC now owns 122,472 shares of the medical device company's stock valued at $1,912,000 after buying an additional 34,210 shares during the period. Lazard Asset Management LLC purchased a new position in shares of Orthofix Medical in the fourth quarter valued at $45,000. Raymond James Financial Inc. purchased a new stake in Orthofix Medical during the 4th quarter worth $1,003,000. Finally, JPMorgan Chase & Co. increased its stake in Orthofix Medical by 244.1% during the 4th quarter. JPMorgan Chase & Co. now owns 290,351 shares of the medical device company's stock worth $5,070,000 after buying an additional 205,972 shares during the period. Hedge funds and other institutional investors own 89.76% of the company's stock.

Orthofix Medical Trading Up 2.4%

Shares of NASDAQ OFIX traded up $0.26 during mid-day trading on Friday, hitting $10.97. The company's stock had a trading volume of 633,357 shares, compared to its average volume of 274,344. The stock has a market cap of $429.82 million, a price-to-earnings ratio of -3.50 and a beta of 0.80. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.39 and a quick ratio of 1.11. Orthofix Medical Inc. has a one year low of $10.50 and a one year high of $20.73. The company's fifty day simple moving average is $12.82 and its 200-day simple moving average is $16.07.

Insider Buying and Selling

In other news, CEO Massimo Calafiore acquired 10,000 shares of Orthofix Medical stock in a transaction on Friday, May 9th. The shares were purchased at an average cost of $12.54 per share, for a total transaction of $125,400.00. Following the completion of the purchase, the chief executive officer now directly owns 234,603 shares of the company's stock, valued at approximately $2,941,921.62. This represents a 4.45% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Engine Capital Management, Lp bought 100,000 shares of the company's stock in a transaction dated Wednesday, May 7th. The stock was bought at an average cost of $12.31 per share, with a total value of $1,231,000.00. Following the acquisition, the insider now directly owns 3,544,807 shares of the company's stock, valued at approximately $43,636,574.17. The trade was a 2.90% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 112,250 shares of company stock valued at $1,380,970 and have sold 8,475 shares valued at $128,065. 1.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

OFIX has been the subject of several research reports. JMP Securities reaffirmed a "market perform" rating on shares of Orthofix Medical in a report on Friday. Wall Street Zen lowered shares of Orthofix Medical from a "hold" rating to a "sell" rating in a research note on Friday. Roth Mkm reiterated a "buy" rating and issued a $22.00 price objective on shares of Orthofix Medical in a research note on Wednesday, February 26th. Finally, Canaccord Genuity Group restated a "buy" rating and set a $24.00 price target on shares of Orthofix Medical in a research note on Wednesday, February 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Orthofix Medical currently has an average rating of "Hold" and an average price target of $23.33.

Orthofix Medical Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.